Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma

Inclusion Criteria: * 16 years or older; * diagnosis of an advanced unresectable or metastatic soft tissue sarcoma, of intermediate or high grade, for which no standard curative therapy is available; * cumulative dose of anthracycline antibiotic ≥ 300mg/m2; * stable or responsive to doxorubicin, potential beneficiary; * an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, a life expectancy of at least 3 months; * measurable disease according to RECIST 1.1; * adequate end-organ and haemopoietic function. Exclusion Criteria: * progress over doxorubicin; * previous mediastinal or cardiac radiotherapy; * a low-grade tumour according to standard grading systems (eg, American Joint Committee on Cancer grade 1 and 2 or Fédération Nationale des Centres de Lutte Contre le Cancer grade 1); * significant cardiac dysfunction; * severe chronic obstructive pulmonary disease; * a known infection with HIV or active infection with hepatitis B or hepatitis C; * known brain metastases unless previously treated and well controlled for a period of 3 months or longer; * combination with other anti-tumor therapy; * pregnant or breastfeeding.